ContractSupplemental Retention Benefits Letter Agreement • May 12th, 2021 • Minerva Neurosciences, Inc. • Pharmaceutical preparations
Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.
April 27, 2021 Re:Supplemental Retention Benefit Dear __________:Executive Supplemental Retention Benefits Letter Agreement • May 12th, 2021 • Minerva Neurosciences, Inc. • Pharmaceutical preparations
You will recall that last year the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) adopted a retention program for certain of its key employees, pursuant to which the Company provided certain cash and equity incentives designed to retain employees (the “Retention Program”).
ContractSupplemental Retention Benefits Letter Agreement • May 12th, 2021 • Minerva Neurosciences, Inc. • Pharmaceutical preparations
Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.
